Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: February 15, 2024
Event Date: February 14, 2024
Context: The Company entered into a Warrant Inducement Agreement with an institutional investor to facilitate the exercise of previously issued Series B Warrants, ensuring compliance with Nasdaq listing rules.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.0 million from the full cash exercise of the Series B Warrant.
- Exercise Price: $4.02 per share (adjusted for Nasdaq compliance).
- Shares Underlying Exercise: 980,393 shares of Common Stock.
- Transaction Costs: A cash fee of 7.0% of gross proceeds (approx. $280,000) plus up to $30,000 in legal expense reimbursement to financial advisor A.G.P./Alliance Global Partners.
- Use of Proceeds: General working capital and general corporate purposes.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, or cash flow data for a reporting period.
Material Changes and New Agreements
The primary material change is the execution of the Inducement Transaction, which includes:
- Warrant Exercise: The Holder agreed to exercise the entirety of the Series B Warrant for cash.
- New Warrant Issuance: In consideration for the exercise, the Company issued two new warrants (Inducement Warrants):
- Series B-1: 5-year term, 735,296 shares, exercise price $5.05.
- Series B-2: 18-month term, 735,296 shares, exercise price $5.05.
- Registration Requirements: The Company must file a resale registration statement by April 5, 2024, and use commercially reasonable efforts to make it effective within 60 days.
- Issuance Restrictions: The Company is prohibited from issuing new equity or filing new registration statements (except the required resale statement) for 45 days post-closing and is barred from "variable rate transactions" for six months post-effectiveness.
Outlook, Risks, and Contingencies
- Closing Conditions: The transaction is expected to close no later than February 20, 2024, subject to customary conditions.
- Liquidated Damages: The agreement includes provisions for liquidated damages if Inducement Warrant Shares are not timely delivered upon future exercise.
- Warrant Features: Inducement Warrants include anti-dilution protection, cashless exercise provisions (if unregistered), beneficial ownership limitations, and a put right for cash redemption in the event of a Fundamental Transaction.
- Regulatory Risk: Failure to timely register the Inducement Warrant Shares could trigger cashless exercise provisions or other contractual penalties.
Investor Verification Checklist
- Verify the closing of the Inducement Transaction by February 20, 2024.
- Confirm the filing of the Resale Registration Statement by April 5, 2024.
- Monitor the Company's compliance with the 45-day issuance blackout period and the 6-month variable rate transaction prohibition.
- Review the impact of the new warrants (1,470,592 shares total) on potential future dilution.
- Check subsequent filings for the actual net proceeds received after deducting the 7% advisory fee and legal expenses.